EWA
RDHL

EverSource Wealth Advisors’s Redhill Biopharma RDHL Stock Holding History

EverSource Wealth Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38
Closed -$39 – 4482
2025
Q4 		$39 Hold
38
– – ﹤0.01% 4190
2025
Q3 		$82 Buy
+38
New +$62 ﹤0.01% 4218

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EverSource Wealth Advisors's RDHL Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Redhill Biopharma (RDHL) in Q1 2026, closing a stake of 38 shares — an estimated $39 sold.

EverSource Wealth Advisors first reported a position in RDHL in Q3 2025 and held it in 2 quarters. The position peaked at $82 in Q3 2025. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2026.

  • EverSource Wealth Advisors reported no remaining Redhill Biopharma position as of Q1 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 38 Redhill Biopharma shares in Q1 2026, an estimated $39.
  • EverSource Wealth Advisors first reported a position in Redhill Biopharma in Q3 2025 and held it in 2 quarters.
  • EverSource Wealth Advisors's Redhill Biopharma position peaked at $82 in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.